December 06, 2021

Health Canada Approves Nutrasource’s Expanded Research Capabilities in Controlled Drugs & Substances

Guelph, ON –  Nutrasource Pharmaceutical and Nutraceutical Services, a global full-service contract research organization (CRO), has announced the approval of an amendment to their Controlled Drugs & Substances Dealer’s Licence issued by Health Canada earlier this year.

This licence was expanded to include a number of controlled Psychedelic and Psychostimulant drugs and pain management drugs including but not limited to:

  • Psilocybin
  • Psilocin
  • Ketamine
  • LSD
  • Methamphetamines
  • Synthetic Cannabinoids
  • Opioids
  • DMT

“This initiative is a natural progression building and diversifying our portfolio of licences including our Institution-Wide Cannabis Research Licence and Cage Level Security Licence. We are pleased to continue supporting our current and future clients in the areas of pharmaceutical development with botanical agents, psychedelics, and opioid alternatives” said Joshua Baisley, Vice President, Clinical Design and Delivery.

This new approval will enable Nutrasource clients a unique opportunity to conduct early-stage clinical studies, including BA/BE (Bioavailability / Bioequivalence) studies, proof of concept studies on many novel controlled substances in Canada.

There are a myriad of factors contributing to a surge of research with controlled drugs and substances. These include social, political, economic, and regulatory paradigm shifts emerging across the globe in multiple jurisdictions.

As a result, there is an increased interest from the pharmaceutical and biotechnology industries in opioid alternatives and drugs of abuse, along with other agents related to the central nervous system and neurology (anxiety, mood, depression, Alzheimer’s, pain management).

“Working with sponsors in the Natural Health Product industry, we often see a transition into the pharmaceutical space as an avenue for innovation. Obtaining this licence further fulfills Nutrasource’s mission of helping health companies launch scientifically substantiated products and align with our expanded pharmaceutical regulatory services,” said Tania John, Vice President, NHP & Pharmaceutical Regulatory Sciences. “Ultimately, this higher level of security allows us to better serve our clinical and regulatory clients, including those interested or already in the controlled drugs and substances sector.”

Learn more about Nutrasource: Download Capabilities and Services Overview


Nutrasource is a leading nutraceutical and pharmaceutical life sciences company focused on helping clients commercialize health and wellness products. In addition to a unique offering of clinical trial management, strategic and regulatory support services along with a state-of-the-art clinical trial site, Nutrasource offers a series of third party natural ingredient certification programs (IFOS™, IGEN™, IPRO™, ICAP™) and the NutraStrong™ POC (Point-of-Care) technology platform.